Vimarsana
Biggest News Aggregation in the World

Eric Schoen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eric Schoen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eric Schoen Today - Breaking & Trending Today

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ - Vimarsana News

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

End-of-day, Thursday, May 2, 2024, Will be the Last and Final Day to Trade SAVAW Warrants on NASDAQ.Monday, May 6, 2024, Will be the Last and Final Day to Cash-Exercise SAVAW Warrants.‘Notice of...

Cassava Sciences : Corporate Presentation – First Quarter 2024 -March 25, 2024 at 09:36 am EDT - Vimarsana News

Cassava Sciences : Corporate Presentation – First Quarter 2024 -March 25, 2024 at 09:36 am EDT

Corporate Overview First Quarter 2024 Forward-Looking Statements & Other Notices Cassava Sciences is in the business of new drug discovery...

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials - Vimarsana News

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

An Independent Data and Safety Monitoring Board Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials...

Cassava Sciences Reports Full-year 2023 Financial Results - Vimarsana News

Cassava Sciences Reports Full-year 2023 Financial Results

$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over...

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months - Vimarsana News

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer’s Patients Who Received Simufilam...